LISATA THERAPEUTICS, INC. Stock-Based Compensation
LISATA THERAPEUTICS, INC. (LSTA) reported Stock-Based Compensation of $578.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- LISATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $214.00K, a 10.46% decline year-over-year.
- LISATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $364.00K, a 31.32% decline year-over-year.
- LISATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $239.00K.
- LISATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $530.00K.
- LISATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $1.23M, a 25.83% decline from fiscal 2024.
- LISATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $1.65M, a 18.89% decline from fiscal 2023.
- LISATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $2.04M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $214.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $578.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $364.00K 10-Q · filed 2026-05-11 | ||
| 2025-12-31 | $1.23M 10-K · filed 2026-03-12 | ||
| 2025-06-30 | $239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $769.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $530.00K 10-Q · filed 2026-05-11 | ||
| 2024-12-31 | $1.65M 10-K · filed 2026-03-12 | ||
| 2023-12-31 | $2.04M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |